Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 5/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502110 | 0.88 | SRC (0.51) | SRCFGFR1BRPF1MEN1NPC1 | |
| SCHEMBL854684 | 0.85 | SRC (0.44) | SRCFGFR1BRPF1MEN1NPC1 | |
| SCHEMBL502056 | 0.83 | MAPK14 (0.54) | SRCFGFR1BRPF1ALDH1A1MAPK14 | |
| SCHEMBL14145303 | 0.82 | SRC (0.40) | SRCFGFR1FGFR4MAPK14WEE1 | |
| SCHEMBL502067 | 0.82 | ALDH1A1 (0.41) | SRCFGFR1BRPF1MEN1NPC1 | |
| SCHEMBL502525 | 0.81 | MAPK14 (0.53) | SRCFGFR1ALDH1A1NPSR1MAPK14 | |
| SCHEMBL880924 | 0.80 | BRPF1 (0.49) | SRCFGFR1BRPF1MEN1NPC1 | |
| SCHEMBL854801 | 0.79 | SYK (0.41) | SRCFGFR1EGFRFGFR4MAPK14 | |
| SCHEMBL854800 | 0.79 | SYK (0.41) | SRCFGFR1EGFRFGFR4MAPK14 | |
| SCHEMBL10272342 | 0.79 | SYK (0.41) | SRCFGFR1EGFRFGFR4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102083828-B | Heterocyclic compounds and compositions as C-KIT and PDGFR kinase inhibitors | IRM LLC | 2013-11-13 | — | — | CN | disclosed |
| US-8278452-B2 | Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-10-02 | — | — | US | disclosed |
| US-8278452-B2 | Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-10-02 | — | — | US | disclosed |
| US-8278452-B2 | Heterocyclic compounds and compositions as c-kit and PDGFR kinase inhibitors | IRM LLC (BM) | 2012-10-02 | — | — | US | disclosed |
| EP-2252612-B1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2012-03-28 | — | — | EP | disclosed |
| EP-2252612-B1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2012-03-28 | — | — | EP | disclosed |
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-20110183997-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2011-07-28 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| WO-2009105712-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2009-08-27 | — | — | WO | disclosed |
| WO-2009105712-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | IRM LLC (BM) | 2009-08-27 | — | — | WO | disclosed |
| EP-2076513-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2009-07-08 | — | — | EP | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| WO-2008051757-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051757-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | SRC 3/4885FGFR1 34/4885BRPF1 1311/4885 |
| US-20110183997-A1 | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | SRC 302/4885FGFR1 208/4885BRPF1 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.